Basecare is on the list strongly [2020 vote in the list. Rui company 100 list]
Recently, China Investment Research Institute released the "2020 China Investment List• Sharp Companies 100 List". The list is selected based on the three dimensions of the company's external attention, industrial synergy, and industrial influence. Basecare, the leading innovation platform for genetic testing solutions for assisted reproduction in China, stood out from more than 800 participating companies with strong comprehensive strength and is the only NGS assisted reproduction company on the list.
At present, technological and industrial changes are becoming more and more intense, and the wave of innovation economy and digital economy is sweeping the world, and is becoming a new engine of global development. Realizing breakthroughs in key technological innovation has become a top priority. The new economy has entered a stage of high-quality development from rapid development. Whether it is technological innovation or model innovation, China's innovative economy enterprises have shown an unstoppable trend internationally. It is against this background that China Investment Group launched the selection of innovative economic sharp companies for the first time, aiming to discover participants and witnesses in a new round of reform. In such a new economic wave, Beikang Medical has successively obtained recognition from the industry and investors, as well as government agencies, with its outstanding innovative technology research and development capabilities. As China’s leading innovative platform for assisted reproductive genetic testing solutions, the third-generation test tube PGT-A test kit independently developed by Basecare also obtained the industry’s first Class III medical device registration certificate this year (National Machinery Note: 20203400181) , Fills the technical gap of the third-generation test tube clinical application in my country, marks the official entry of the third-generation test tube PGT-A test into the era of certification, and at the same time establishes Beikang Medical’s leading position in this field. After the PGT-A kit was approved for marketing, the National Medical Products Administration immediately issued an announcement that from August 1, 2020, the PGT-A kit was included in the mandatory pharmaceutical industry standard. Article 6 of the "Regulations" stipulates that "Medical device products shall comply with the mandatory national standards for medical devices; if there are no mandatory national standards, they shall comply with the mandatory industry standards for medical devices." All relevant units shall fully understand the laws of mandatory industry standards Position, earnestly maintain the authority of mandatory industry standards, and ensure that mandatory industry standards are standardized and effectively implemented.
According to Frost & Sullivan’s research data, the scale of the third-generation IVF market has increased from RMB 300 million in 2015 to RMB 2.5 billion in 2019, with a compound annual growth rate of 70.8%, and is expected to reach RMB in 2024 25.5 billion yuan, with a compound annual growth rate of 58.6% from 2019 to 2024.
The innovative technology of the third-generation test tube baby provides new options for infertile couples and new hope for pregnant couples with genetic diseases. The third-generation test tube PGT-A kit will become a rigid clinical need. It is precisely due to the continuous development of the market that the operation and use of medical devices are also facing increasingly stringent legal requirements and compliance challenges, and the use of certified medical devices in the future is also an inevitable development trend. Medical institutions and medical staff should also strengthen their awareness of medical safety and risk prevention, use medical devices legally and compliantly, and avoid various risks caused by the use of unlicensed products.
This time, Basecare's ranking on the "Top 100 Best Companies in the 2020 Investment List" is the industry's recognition of Basecare's leading position in China's third-generation IVF genetic testing kit market. In the future, Basecare will always adhere to the simple and pure dream of "allowing more families to have healthy babies, so that there are no "difficult" children in China", and will move toward becoming the world's leading genetic technology company with an unstoppable momentum. Make our lives better and make our offspring healthier.